JOURNAL of
ONCOLOGICAL
SCIENCES

ORIGINAL RESEARCH ARTICLE

First line modified Folfirinox versus gemcitabine for advanced pancreatic cancer: A single institution retrospective experience
Received Date : 18 Sep 2018
Accepted Date : 04 Mar 2019
Doi: 10.1016/j.jons.2019.03.002 - Article's Language: EN
J Oncol Sci 5 (2019) 1-5
This is an open access article under the CC BY-NC-ND license
ABSTRACT
Background:Advanced pancreatic cancer (APC) is a highly lethal malignancy which has one of the worsttreatment outcomes. Modified (m)FOLFIRINOX is an intense but a proven treatment approach with asurvival benefit for APC. Although mFOLFIRINOX demonstrated survival benefit compared with gemci-tabine monotherapy, the standard treatment in previous years, toxicity is a difficult aspect of thistreatment.Methods:A retrospective analysis of patients referred to Medical Oncology Clinics of Ankara OncologyResearch and Training Hospital with the diagnosis of inoperable locally advanced or metastaticpancreatic cancer and treated with mFOLFIRINOX or gemcitabine monotheraphy from March 2013 toApril 2018 was performed.Results:Forty three patients and 37 patients were included in mFOLFIRINOX and gemcitabine groups,respectively. The mean age of the patients was 53.74 years (range: 32e69) and 65,7 years (range: 47e82)for mFOLFIRINOX and gemcitabine, respectively (95% CI, p<0.001). All patients, except one, had ECOGperformance status of 0 or 1 in mFOLFIRINOX group. In contrast, nine patients had ECOG performancestatus of 2 in the gemcitabine group (95% CI, p¼0.002). When the patients were evaluated for response,11 (25.6%) and 6 (16.2%) had partial remission with mFOLFIRINOX and gemcitabine, respectively. MedianPFS and OS was 5,73 (95% CI, 2,57-8,90) months and 8.77 (95% CI, 6.54e10.99) months with mFOLFIR-INOX and 2,77 (95% CI, 2,29-3,24) months and 5.80 (95% CI, 3.08e7.92) months with gemcitabine,respectively. mFOLFIRINOX regimen was more toxic than gemcitabine regimen. The incidences of all-grade neutropenia, neuropathy, and emesis were more prominent in the mFOLFIRINOX group.Conclusion:mFOLFIRINOX is a difficult regimen for both patients and physicians with significant toxicitywith a greater survival benefit. The survival benefit was modest in this real-life experience. Patient se-lection bias and small sample size of this retrospective study should be considered.
KAYNAKLAR
  1. GLOBOCAN. Estimated Cancer _Incidance, Mortality and Prevalence Worldwide in 2012. http://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN- 2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In- 2012-V1.0-2012. Accessed September 28, 2018.
  2. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Pancreatic Cancer. https://seer.cancer.gov/statfacts/html/pancreas.html. Accessed September 28, 2018.
  3. Conroy T, Desseigne F, Ychou M, et al. GroupeTumeurs Digestives of Unicancer; PRODIGE Intergroup, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817e1825.
  4. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691e1703.
  5. Ozaka M, Ishii H, Sato T, et al. A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2018;81(6):1017e1023. [Crossref]  [PubMed] 
  6. Yoshida K, Iwashita T, Uemura S, et al. A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer. Oncotarget. 2017;8(67):111346e111355. [Crossref] 
  7. Chllamma MK, Cook N, Dhani NC, et al. FOLFIRINOX for advanced pancreatic cancer: the princess margaret cancer centreexperience. Br J Canc. 2016;115(6): 649e654. [Crossref]  [PubMed] 
  8. Burris 3rd HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6): 2403e2413. [Crossref]  [PubMed] 
  9. Ciliberto D, Botta C, Correale P, et al. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer. 2013;49(3):593e603. [Crossref]  [PubMed] 
  10. Sun C, Ansari D, Andersson R, Wu DQ. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol. 2012;18(35):4944e4958. [Crossref]  [PubMed]  [PMC] 
  11. Ho MY, Kennecke HF, Renouf DJ, et al. Defining eligibility of FOLFIRINOX for first-line metastatic pancreatic adenocarcinoma (MPC) in the province of British columbia: a population-based retrospective study. Am J Clin Oncol. 2017;40(6):552e554. [Crossref]  [PubMed] 
  12. Tahara J, Shimizu K, Otsuka N, et al. Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2018;82(2):245e250. [Crossref]  [PubMed] 
  13. Todaka A, Mizuno N, Ozaka M, et al. Nationwide multicenter observational study of FOLFIRINOX chemotherapy in 399 patients with unresectable or recurrent pancreatic cancer in Japan. Pancreas. 2018;47(5):631e636. [Crossref]  [PubMed] 
  14. Ghorani E, Wong HH, Hewitt C, et al. Safety and efficacy of modified FOLFIRINOX for advanced pancreatic adenocarcinoma: a UK single-centre experience. Oncology. 2015;89(5):281e287. [Crossref]  [PubMed] 
  15. Cartwright TH, Parisi M, Espirito JL, et al. Clinical outcomes with first-line chemotherapy in a large retrospective study of patients with metastatic pancreatic cancer treated in a US community Oncology setting. Drugs Real World Outcomes. 2018;5(3):149e159. [Crossref]  [PubMed]  [PMC] 
  16. Tong H, Fan Z, Liu B, Lu T. The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. Sci Rep. 2018;8(1):8666. [Crossref]  [PubMed]  [PMC]